By HealthDataConsortium.org Research Team. Sources opened and checked October 2, 2026. This is an independent educational publication. It has not been clinically or peer reviewed and is not medical advice.
A lion's mane trial tells you what happened to a specific group of people who took a specific product for a specific time, measured in a specific way. It does not tell you what any supplement on a shelf will do for you. This guide shows you how to pull those pieces out of a study so you can read a result without overreading it.
The Short Answer: Six Questions to Ask of Any Lion's Mane Study
Before you look at a result, find these six things. Each one limits what the result can mean.
- Population: Who was studied? Age, health status, and sample size.
- Product: What exactly was taken? Fruiting body, mycelium, or an extract, and the daily amount.
- Duration: How long did people take it, and when was the outcome measured?
- Outcome: Which test or scale was used, and how many different outcomes were measured?
- Result: Was the product group compared with a placebo group, or only with its own starting point? Did the result hold across several measures?
- Limitation: Who supplied or paid for it, how big was it, and what did the authors themselves say they could not conclude?
Annotated Evidence Guide: Two Trials in Plain Language
The two trials below are real, published studies whose full text we opened for this article. They were chosen because they differ in almost every way, which makes the differences easy to see. Each entry reads: what the study reports, then what it means in plain language.
Trial A: Docherty and colleagues, Nutrients, 2023
- Population. The study: 41 healthy adults aged 18 to 45 (43 enrolled, 2 stopped). In plain language: healthy young adults. It says nothing direct about older adults or people with memory problems.
- Product. The study: 1.8 g per day of a Hericium erinaceus product (SO-DSX1), taken as three 600 mg capsules, versus placebo. In plain language: the result belongs to that product and dose. A different brand, form, or dose is a different test.
- Duration. The study: 28 days of daily use, with tests 60 minutes after a single dose on day 1 and again on day 29. In plain language: this looks at one-hour effects and about one month, not long-term use.
- Outcome. The study: the Stroop task (a speed-and-attention test), word recall, working memory, reaction time, stress scales, and mood scales. In plain language: many outcomes were measured. When many are measured, some can look better or worse by chance, so a single standout number deserves caution.
- Result. The study: participants were faster on the Stroop task 60 minutes after a single dose (p = 0.005); they gave fewer correct responses on immediate word recall after the single dose (p = 0.013); and a trend toward lower stress after 28 days was observed (p = 0.051). The abstract also reports that null and limited negative findings were observed. In plain language: a mixed picture. One speed result was better, one memory result was worse, the stress result was a trend rather than a clear finding, and many measures showed no effect.
- Limitation. The study: the authors describe the small sample as an inherent limitation of a pilot trial and say it was likely underpowered to detect modest effects in healthy people. They also say the cognitive tests may not have been demanding enough and that the 60-minute timing may have been too short. The product was provided by Sempera Organics, which the authors say had no role in study design, analysis, writing, or the decision to publish. In plain language: a small pilot can suggest what to test next. It cannot settle whether a product works.
Trial B: Li and colleagues, Frontiers in Aging Neuroscience, 2020
- Population. The study: 49 people with mild Alzheimer's disease were randomized and 41 completed it (20 in the product group, 21 in the placebo group). Average age was about 74 in the product group and about 77 in the placebo group. In plain language: older adults with a diagnosed condition. This is a different question from the one asked in healthy young adults, and neither result transfers to the other group.
- Product. The study: three 350 mg capsules daily of erinacine A-enriched Hericium erinaceus mycelia (5 mg/g erinacine A). In plain language: a specific mycelium preparation enriched for one compound. It is not the same thing as a generic lion's mane capsule.
- Duration. The study: 49 weeks of treatment after a 3-week screening. In plain language: nearly a year, much longer than Trial A.
- Outcome. The study: cognitive and daily-living measures (including the Mini-Mental State Examination, or MMSE, and an Instrumental Activities of Daily Living, or IADL, score), plus eye exams, blood markers, and brain MRI. In plain language: several different kinds of measures. Lab and imaging findings are not the same as feeling or functioning better.
- Result. The study: in the product group, MMSE scores rose from 21.75 to 23.2 (p = 0.035), while the placebo group showed no significant change across time points. The two groups also differed significantly on the IADL score at week 49 (p = 0.012). In plain language: scores favored the product group in this small trial. Note the difference between a rise within one group and a difference between the two groups. The between-group comparison is the stronger kind of evidence, so check which one a claim is using.
- Limitation. The study: the authors call it a pilot and write that a larger study is required. Four participants dropped out because of abdominal discomfort, nausea, or skin rash, and the authors say that because older patients often take several medicines, it is hard to tell whether such events were caused by the product. The manufacturer, Grape King Bio Inc., supported the work with salaries for some authors and research materials. In plain language: the company that makes the preparation helped run the study. That does not make the result wrong, but it is exactly why independent repeat studies matter.
Worked Example: Checking a Marketing Claim Against the Evidence
Imagine a label that says a lion's mane capsule is “clinically shown to support memory.” Here is how the guide above handles it.
- Which trial could it mean? If it points to Trial B, the population was older adults with mild Alzheimer's disease and the product was an erinacine A-enriched mycelium. A capsule that is not that preparation was not tested in that trial.
- If it points to Trial A, the result was mixed: one speed measure improved after a single dose, immediate word recall was worse, and the stress finding was only a trend. “Supports memory” does not match that.
- What does “clinically shown” leave out? Small samples (41 people in each study), the duration, who supplied or funded the product, and the authors' own statements that the studies were pilots and that larger trials are needed.
The fair reading is narrower than the label: small, early studies tested specific products in specific groups and produced results that need confirming. That is a more useful sentence than the slogan, and it is the one the evidence supports.
Why a Small Difference in a Number Is Easy to Overread
A p-value is a rough signal of how surprising a difference would be if the product did nothing. It does not measure how large or how useful a difference is. In Trial A, a p of 0.005 on a one-hour speed test cleared the conventional 0.05 cut-off, while a p of 0.051 for stress narrowly missed it. Neither number says how big the effect was or whether it would matter in daily life. Also look at how many outcomes were tested: the more outcomes a study measures, the more likely it is that one looks good by chance, and the Trial A authors acknowledge running numerous analyses. This is a general principle of reading trials, not a finding of either study.
What a Trial Cannot Establish About Your Product
- It cannot confirm that a different brand works the same way. Form, extraction, and dose differ between products.
- It cannot cover groups it did not include. Healthy young adults and older adults with a diagnosis are different questions.
- It cannot establish long-term safety or effects beyond the weeks or months it ran.
- It cannot tell you how the product interacts with your medicines. Our guide to lion's mane and medication interactions covers the four medication classes it flags for caution, which is a question to bring to a pharmacist or prescriber.
- It cannot replace regulatory review. The NIH Office of Dietary Supplements notes that there are no provisions in the law for the FDA to approve dietary supplements for safety or effectiveness before they reach the consumer, and that the amount of scientific evidence available for various supplement ingredients varies widely.
Who Should Seek Professional Advice
Talk with a doctor, pharmacist, or registered dietitian before starting any supplement if you take prescription medicines, are pregnant or breastfeeding, are preparing for surgery, or have a health condition. The same is true if you are worried about memory changes, which deserve a proper evaluation rather than a supplement trial. The NIH Office of Dietary Supplements encourages people to talk to their health care providers about their interest in, questions about, or use of dietary supplements.
What You Can Do Next
- Pick any lion's mane study you see cited and fill in the six questions from the top of this page. If you cannot answer one, treat that as a gap, not a good sign.
- Compare the study's product and dose with the one you are considering. If they differ, the result does not carry over cleanly.
- Read the funding and conflict statements, which are in the full text.
- For a look at what three specific trials found, see our companion piece, Lion's Mane Supplement 2026: What 3 Trials Actually Found.
- Bring your questions and your medication list to a pharmacist or physician.
Sources
The pages below were opened and checked on October 2, 2026. Details in this article are limited to what those pages state.
- Docherty S, Doughty FL, Smith EF. The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study. Nutrients. 2023. mdpi.com/2072-6643/15/22/4842
- Li IC, Chang HH, Lin CH, et al. Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study. Frontiers in Aging Neuroscience. 2020. frontiersin.org (full text)
- NIH Office of Dietary Supplements, Dietary Supplement Fact Sheets for Consumers. ods.od.nih.gov
This article is educational and does not diagnose, treat, or recommend a supplement for any person. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease.
